false
0001725255
0001725255
2026-07-06
2026-07-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 6, 2026
AdaptHealth
Corp.
(Exact name of registrant as specified in its
charter)
| Delaware | |
001-38399 | |
82-3677704 |
(State
or other jurisdiction of
incorporation) | |
(Commission
File Number) | |
(IRS
Employer Identification No.) |
555 East North Lane, Suite
5075
Conshohocken, PA |
|
19428 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
| |
|
|
| (610)
424-4515 |
(Registrant’s
telephone number, including area code)
|
Not
Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to
Section 12(b) of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which
registered |
| Common Stock, par value $0.0001 per share |
|
AHCO |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 7.01. Regulation FD Disclosure. |
|
On July 6, 2026, AdaptHealth LLC (the “Issuer”),
an indirect wholly-owned subsidiary of AdaptHealth Corp. (the “Company”), issued a notice of redemption for all of its outstanding
6.125% Senior Notes due 2028 (the “Notes”) in an aggregate principal amount of $325,000,000 (the “Redemption”),
at a redemption price equal to 100% of the aggregate principal amount of the Notes to be redeemed, plus accrued and unpaid interest on
such Notes to, but not including, the redemption date (the “Redemption Price”). The Redemption will be conditioned upon receipt
by the Issuer or any of its subsidiaries of the net proceeds of a borrowing under its existing delayed draw term loan facility in an aggregate
principal amount sufficient to pay the Redemption Price (the “Redemption Condition”). The date of redemption is expected to
be August 1, 2026 (the “Redemption Date”), subject to the satisfaction of the Redemption Condition. Pursuant to the indenture
governing the Notes, payment of the Redemption Price is expected to occur on the next succeeding business day following the Redemption
Date, which is August 3, 2026, and no interest will accrue for the period from and after the Redemption Date.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: July 7, 2026
| AdaptHealth Corp. |
|
| |
|
| By: |
/s/ Jason Clemens |
|
| |
Name: |
Jason Clemens |
|
| |
Title: |
Chief Financial Officer |
|
